Patients Sue GLP-1 Drugmakers Over Vision Loss Risk
Left 50%
Center 50%
Right 0%
1 left · 1 center · 0 right
What happened
Hundreds of Americans have filed personal injury lawsuits against the makers of GLP-1 diabetes and weight-loss drugs including Ozempic, Wegovy, and Mounjaro, alleging the companies failed to warn of a risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition in which disrupted blood flow to the optic nerve causes sudden, usually permanent, painless vision loss. In one lawsuit, Kentucky woman Sandra Godby says she developed NAION in her left eye after taking Ozempic and Wegovy as prescribed, resulting in severe, permanent vision loss and “radical changes” to her lifestyle. Researchers began examining a possible connection after a 2024 safety signal from a Boston health center; studies since then have produced conflicting results, and no study has established that the medications cause NAION. A 2026 consensus statement from the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society said some studies suggest a small possible increased risk while others found no association, with the overall magnitude of the risk remaining low. Novo Nordisk, maker of Ozempic and Wegovy, said it believes the U.S. lawsuits are “without merit”; Eli Lilly, maker of Mounjaro and Zepbound, said it continuously monitors safety information, including potential ophthalmic issues; the FDA does not require NAION to be listed on the drugs’ labels and said it is reviewing the potential safety signal.
Sourcing check · Mostly on the record · 2 articles
1 of 2 articles cite a named source for the story. It was on the record from the first report. Novo Nordisk denied part of it on the record.
What these terms mean and how they're counted
- On the record · names a source 1 of 2
- On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: Sandra Godby, Eli Lilly, American Academy of Ophthalmology and North American Neuro-Ophthalmology Society and FDA
- Primary evidence · cites a document or data 0 of 2
- Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: None cited.
- Credits another outlet 0 of 2
- The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
- Unnamed sources 0 of 2
- The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
- On-record denial 1
- A named person or institution says the claim, or part of it, is not true. It is on the record — someone signed their name to it — but it is not confirmation, so it never counts toward On the record. Criticizing or dissenting from a decision is not a denial. The count is how many people or institutions deny it; each is listed with the first article that carried the denial. Here: Novo Nordisk (Daily Wire, Sep 22, 10:21 UTC)
- How it developed
- When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Sep 22, 10:21 UTC by Daily Wire, naming its source.
- Not counted 0
- Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
Omitted — what each side leaves out
Unpacked
The story changes if the vision loss is unproven. Left-leaning coverage states only that patients say companies "failed to warn" them of a rare condition that causes vision loss. Right-leaning coverage reports that studies conflict and none have shown the drugs cause it. It also notes the FDA does not require the condition on the label. A reader of only the left-leaning version would treat the risk as known and withheld.
Right-leaning coverage leads with the lawsuits and a Kentucky patient's permanent vision loss, then later reports that any extra risk remains low. Left-leaning coverage never gets past the patients' warning claim, so the scientific doubt never appears.
None of the coverage says how often the same eye condition strikes comparable patients who never took the drugs.
Bottom line
If you read only The Hill, Ozempic makers hid a known vision-loss risk. Daily Wire is the account that reports no study has shown the drugs cause it.
The receipts — 5 facts one side's coverage lacks
- No study has established that GLP-1 drugs cause NAION; studies have produced conflicting results
- Novo Nordisk said the U.S. personal injury lawsuits are without merit
- Hundreds of Americans have filed personal injury lawsuits against makers of Ozempic, Wegovy, and Mounjaro
- Diabetes, overnight low blood pressure, and a small optic nerve cup are established NAION risk factors independent of GLP-1 use
- A 2026 American Academy of Ophthalmology consensus said the overall magnitude of any extra NAION risk remains low
The Left View
The Hill frames the story as patients suing GLP-1 makers over sudden vision loss, centering the patients’ allegation that the pharmaceutical companies “failed to warn them of a risk of a rare condition that causes vision loss.”
The Right View
The Daily Wire frames a “terrifying” side effect at the center of a “growing” legal battle, while stressing that causation is unproven: studies have “produced conflicting results,” and “no study has established that the medications actually cause the condition.” It highlights independent NAION risk factors already common among these patients—diabetes, overnight low blood pressure, and a small optic nerve cup—Novo Nordisk’s view that the lawsuits are “without merit,” and the FDA’s choice so far not to require a specific warning. It also places the vision claims in a wider risk-benefit frame, noting other reported harms such as severe gastrointestinal problems and a boxed warning on thyroid C-cell tumors, alongside significant weight-loss and blood-sugar benefits that doctors “often weigh” against known and still-studied risks.
Our Take (balanced)
The strongest argument on the patient side is the failure-to-warn claim: people who took the drugs as prescribed report sudden, permanent NAION-related vision loss, and that risk was not on the label. The strongest argument on the manufacturers’ side is the scientific record as described in the 2026 ophthalmology consensus—conflicting studies, no established causation, and a low overall magnitude of any possible increased risk—plus overlapping independent risk factors such as diabetes and the FDA’s decision not to require a NAION warning while it reviews the signal. The central unresolved tension is whether a rare, unproven, and low-magnitude association is enough to treat the companies as having failed to warn patients, or whether that standard would require presenting as a known drug risk something that studies have not shown the drugs cause.
2 sources
More stories
The week's bottom lines, in your inbox
One email a week: the five stories that mattered and what they actually mean. Free.